View the latest news and SEC filings
Scroll to
LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024 and host an investment community conference
Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD population LONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces four oral presentations and
One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces one oral presentation
Ohtuvayre TM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona
Date | Form | Filing Group | ||
---|---|---|---|---|
October 25, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
October 25, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
October 22, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
October 22, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
October 18, 2024 |
Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing |
144 |
Other |
|
October 18, 2024 |
Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing |
144 |
Other |
|
September 13, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
September 13, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
September 11, 2024 |
Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing |
144 |
Other |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.